Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038673 · ClinicalTrials.gov registry record · Phase 1
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT02038673 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 86 participants.
The verdict
NCT02038673, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.
Interventions
- DRUG ASP5878
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2013-11-05 |
| Est. Completion | 2017-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038673
The ClinicalTrials.gov registry entry for NCT02038673 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASP5878 is the first listed.
NCT02038673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02038673 about?
NCT02038673 is a clinical study titled "An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors". The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.
What is the current status of trial NCT02038673?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2013-11-05. Estimated completion is 2017-07-19.
What interventions are being tested in trial NCT02038673?
The interventions under investigation include: ASP5878 (DRUG).
Who is sponsoring clinical trial NCT02038673?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.